Human papillomavirus infection

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Retrieved on: 
星期二, 十月 4, 2022
Form 10-Q, E7, Securities Act of 1933, Cancer, Securities Exchange Act of 1934, Analysis, Result, Review, Risk, Papilloma, Nasdaq, Research, CUE, Clinical trial, Drug Quality and Security Act, Food, Selective, Recurrence, Patent, FDA, HPV, Death, OS, COVID-19, Annual report, Metastasis, Financial condition report, Human papillomavirus infection, Policy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, HPV16, Conversation, Patient, Fast Track, Forward-looking statement, Board of directors, Pembrolizumab, Board, GLOBE, Pharmaceutical industry, Vaccine

We are very pleased to have received Fast Track designation from the FDA for CUE-101.

Key Points: 
  • We are very pleased to have received Fast Track designation from the FDA for CUE-101.
  • Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fulfill an unmet medical need.
  • A therapeutic candidate that receives Fast Track designation may be eligible for more frequent interactions with the FDA to discuss the therapeutic candidates development plan.
  • Therapeutic candidates with Fast Track designation may be eligible for accelerated approval and priority review if supported by clinical data.

SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy

Retrieved on: 
星期一, 十月 3, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Frontiers, Vulva, VP, Centers for Disease Control and Prevention, Cancer, Human papillomavirus infection, CD8, U.S. Securities and Exchange Commission, Technology, Risk, SQZ, Immunotherapy, Research, Eryptosis, Private Securities Litigation Reform Act, Man, E6, Virus, Autoimmunity, HPV, Center, COVID-19, Annual report, Infection, Cisplatin, Translation, Immune tolerance, Addition, International Journal of Cancer, Penis, Ageing, Animal, Red blood cell, APC, CDC, NYSE, Canadian International Council, AACS, Confidentiality, AAC, Patient, Cell, Degenerative disease, Publication, Woman, RBC, Therapy, Antigen, Vaccine, Pharmaceutical industry, E7, Immunology

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.

Key Points: 
  • SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ Activating Antigen Carrier (AAC) platform.
  • This paper demonstrates the potential of our technology to generate an effective red blood cell-derived cancer immunotherapy, said Howard Bernstein, M.D., Ph.D., Chief Scientific Officer at SQZ Biotechnologies.
  • We are excited about the preclinical findings of our AAC program, which has shown potential in both monotherapy settings and in combination with chemotherapy, said Scott Loughhead, Ph.D., VP of Translational Research at SQZ Biotechnologies.
  • SQZ AACs are generated by squeezing red blood cells (RBCs) with antigens and activating adjuvant.

The Fenway Institute Offers Recommendations for Improving Human Papillomavirus Vaccination Rates in US

Retrieved on: 
星期日, 十月 2, 2022
Adult, Wart, ACIP, Health, Safety, Sex, LGBT, Anal cancer, COVID-19, Woman, STI, Vaccination, HIV, Population, Life, Loyola University Chicago, Loyola University, Stritch School of Medicine, Patient, White, Fenway Health, Fenway Park, Advisory Committee, Human papillomavirus infection, Vaccine, Head, Federally Qualified Health Center, Gender identity, HPV, Stockholm Environment Institute US Center, Research, Ageing, Parent, PDF, Human, Awareness, Man, Neck, Policy

BOSTON, October 02, 2022  /PRNewswire-PRWeb/ -- A policy brief published by The Fenway Institute at Fenway Health offers recommendations to health professionals and policy makers on how to improve Human Papillomavirus (HPV) vaccination rates in the U.S. HPV is the most common sexually transmitted infection (STI) in the world. Approximately 79 million Americans, most in their teens and early 20s, are infected with HPV despite the widespread availability of a safe and effective vaccine since 2006.

Key Points: 
  • But vaccination rates remain far below optimal rates of coverage, especially among male-identifying individuals.
  • There are other disparities in vaccination rates across populations of varying sexual and gender identities, as well as race and ethnicity.
  • The policy brief, titled "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," addresses barriers to HPV vaccination, including the politicization of vaccines, sex and gender-based stigma, medical mistrust, misinformation, and insufficient provider recommendation.
  • "Improving Human Papillomavirus vaccination rates in the U.S.: Recommendations for health professionals and policy makers," is available for download as a PDF here .

Asia Pacific Travel Vaccines Market Report 2022: Surge in Incidences of Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 27, 2022
Infectious Diseases, Pharmaceutical, Health, Rotavirus, Health, Hepatitis A, COVID-19, Risk, Vaccination, Growth, Hepatitis B, Immunization, Travel, Inactivated vaccine, Human papillomavirus infection, Pneumonia, Vaccine, HPV, Awareness, Infection, CAGR, Aquaculture

The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.
  • The Asia Pacific travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • The Asia Pacific travel vaccines market, based on application, is segmented into domestic travel and outbound travel.
  • Based on country, the Asia Pacific travel vaccines market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific.

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
星期四, 八月 25, 2022
Research, Women, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Transfer, European Society for Medical Oncology, Ministry, Safety, HPV, Merck Sharp & Dohme Federal Credit Union, Human papillomavirus infection, KOSDAQ, Head, CKD, Judgement, Hope, Cervical cancer, Neck, Data analysis, DNA, International Money Transfers System Leader, Goal, Pembrolizumab, Immunotherapy, Therapy, DART, Oncology, Merck, Congress, Merck & Co., MFDS, Patient, Pharmaceutical industry, Vaccine, Food, Korean

We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.

Key Points: 
  • We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics.
  • Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
星期二, 八月 9, 2022
U.S. Securities and Exchange Commission, GLOBE, SEC, Cancer, Security (finance), Knowledge, Annual report, Patient, Nivolumab, G&A, Infection, HBsAg, Immune system, HPV, Prostate cancer, EASL, Private Securities Litigation Reform Act, Degenerative disease, Oxford University Innovation, VTP, Licensure, Safety, Hepatitis B, Investigational New Drug, OUI, University, Hepatitis, Autoimmunity, HBV, MERS, COVID-19, Program, Vaccine, ChAdOx1, AstraZeneca, Arbutus, Vaccitech, IND, MVA, Company, Human papillomavirus infection, NASDAQ, Research, Insurance, Antigen, EMA, Pharmaceutical industry, Renewable energy

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.
  • Second Quarter 2022 Financial Highlights:
    Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021.
  • Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022.
  • Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022.

Global Human Papillomavirus Vaccine Market Forecast to 2028: Advancements in HPV Diagnostics Tests & Growing Number of HPV Awareness Programs - ResearchAndMarkets.com

Retrieved on: 
星期五, 八月 5, 2022
Infectious Diseases, Pharmaceutical, Health, Woman, World Health Assembly, Health care, Cervical cancer, Growth, Adolescence, Incidence, Prevalence, Hospital, Market share, CDC, COVID-19, Human papillomavirus infection, Parent, Vaccine, Transport, Awareness, Wart, CAGR, Vaccination, World, Distribution, HPV, Application, Dose

The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.

Key Points: 
  • The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.
  • Based on type, the human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • The global human papillomavirus (HPV) vaccine market, based on age, is segmented into 9 to 14 years and 15 to 45 years.
  • In terms of application, the global human papillomavirus (HPV) vaccine market is segmented into HPV-attributable cancers and genital warts.

Cervical Cancer Therapeutics Market Research Report 2022: Epidemiology & Pipeline Analysis 2022-2027 - 282+ Trials in Various Phases of Development - ResearchAndMarkets.com

Retrieved on: 
星期二, 七月 26, 2022
Pharmaceutical, Health, Oncology, Knowledge, Diagnosis, Awareness, Human papillomavirus infection, National Comprehensive Cancer Network, Chemoradiotherapy, Food, Angiogenesis, HPV, Bevacizumab, Woman, Adenocarcinoma, Research, Ageing, Histology, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Therapy, Immune system, Classification, Cervical cancer, Age, Profile, CAGR, Squamous cell carcinoma, Clinical trial, PD-L1, FDA, Disease management, Company, Patient, Prevalence, PAP, Growth, HIV, Birth control, Pharmaceutical industry, Vaccine, Medical device, Pembrolizumab, Disease, Epidemiology, Phase

The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development.
  • Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti-P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer.
  • The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer.

Nominations Open for 10th Annual International Harrington Prize for Innovation in Medicine

Retrieved on: 
星期一, 七月 25, 2022
Lecture, University Hospitals Cleveland Medical Center, NHLBI, Association, Antibody, Diabetes, Rockefeller University, NIH, Society, University, NIAMS, Disorder, Sickle cell disease, Doctor of Philosophy, American Physician Scientists Association, CAR, Human papillomavirus infection, Massachusetts General Hospital, Leptin, Lists of diseases, Vanderbilt University, Marfan syndrome, Mount Sinai Hospital, National Cancer Institute, LDL, COVID-19, Cervical cancer, All India Mahila Congress, Thalassemia, Organization, Journal, University of Texas Southwestern Medical Center, Creativity, Science, List, Patient, University of Copenhagen, University of Pennsylvania, Biology, American Society for Clinical Investigation, PCSK9, ASCI, APSA, Johns Hopkins University, AAP, Harvard University, Pharmaceutical industry, Vaccine, Medicine, MD

CLEVELAND, July 25, 2022 /PRNewswire/ -- National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. 

Key Points: 
  • CLEVELAND, July 25, 2022 /PRNewswire/ --National and international nominations are being sought for the 2023 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.
  • The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), one of the nation's oldest and most respected medical honor societies.
  • Harrington Discovery Institute is a nonprofit institute dedicated to helping physician-scientists accelerate promising discoveries into medicines for unmet needs.
  • A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee.

Global Cancer Vaccine Market & Clinical Trials Outlook 2028: HPV Vaccine Sales Fueling Growth With Other Investigational Vaccines in Late Stage Development - ResearchAndMarkets.com

Retrieved on: 
星期四, 七月 21, 2022
Pharmaceutical, Health, Oncology, Algorithm, Awareness, Cervical cancer, BLA, Human papillomavirus infection, Gardasil, Large-cell lung carcinoma, HPV, Cancer, Pancreatic cancer, BCG, Sipuleucel-T, Prostate cancer, Artificial intelligence, US, US FDA, RNA transfection, Machine learning, Company, Patient, Vaccination, Bacillus, Growth, B cell, Vaccine, Pharmaceutical industry

The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The significant increase in the growth of the market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination.
  • Apart from this, several investigational cancer vaccines have progressed towards late-stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.
  • Cancer Vaccines Trials Insight By Company, Country, and Indication
    To date, both therapeutic, as well as preventive cancer vaccines, have gained entry into the global market.